The estimated Net Worth of Saqib Islam is at least $68.6 Million dollars as of 3 September 2024. Mr. Islam owns over 49,000 units of SpringWorks Therapeutics stock worth over $41,109,807 and over the last 12 years he sold SWTX stock worth over $24,177,887. In addition, he makes $3,284,920 as Chief Executive Officer und Director at SpringWorks Therapeutics.
Saqib has made over 18 trades of the SpringWorks Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 49,000 units of SWTX stock worth $1,987,930 on 3 September 2024.
The largest trade he's ever made was selling 62,500 units of SpringWorks Therapeutics stock on 19 July 2021 worth over $4,785,000. On average, Saqib trades about 11,714 units every 115 days since 2013. As of 3 September 2024 he still owns at least 1,063,368 units of SpringWorks Therapeutics stock.
You can see the complete history of Mr. Islam stock trades at the bottom of the page.
Saqib Islam J.D. serves as Chief Executive Officer, Director of the Company. Mr. Islam served as our Chief Financial Officer and Chief Business Officer since our formation in August 2017. Prior to joining SpringWorks, Mr. Islam served as Chief Business Officer at Moderna Therapeutics, Inc. from February 2016 to August 2017. Prior to Moderna, Mr. Islam was Executive Vice President, Chief Strategy and Portfolio Officer at Alexion Pharmaceuticals, Inc. from February 2013 to February 2016, where he was responsible for executing the company’s corporate growth strategies and contributed to its assessment and management of global operations. Prior to joining Alexion, Mr. Islam worked for more than 25 years in international business management with a focus on business development, strategic decision-making and planning and capital markets, previously holding Managing Director positions at Morgan Stanley and Credit Suisse. Mr. Islam has also served on the board of directors of Passage Bio, Inc. since March 2019. Mr. Islam holds a J.D. from Columbia Law School, where he was a Harlan Fiske Scholar, and a Bachelor’s degree from McGill University where he was a Faculty and University
As the Chief Executive Officer und Director of SpringWorks Therapeutics, the total compensation of Saqib Islam at SpringWorks Therapeutics is $3,284,920. There are no executives at SpringWorks Therapeutics getting paid more.
Saqib Islam is 50, he's been the Chief Executive Officer und Director of SpringWorks Therapeutics since 2018. There are 15 older and 3 younger executives at SpringWorks Therapeutics. The oldest executive at SpringWorks Therapeutics, Inc. is Freda Lewis-Hall, 65, who is the Independent Director.
Saqib's mailing address filed with the SEC is C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD, CT, 06902.
Over the last 6 years, insiders at SpringWorks Therapeutics have traded over $386,249,433 worth of SpringWorks Therapeutics stock and bought 800,000 units worth $14,400,000 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Capital Life Sciences Inves... und Jeffrey Lawrence Schwartz. On average, SpringWorks Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $6,795,384. The most recent stock trade was executed by Saqib Islam on 3 September 2024, trading 49,000 units of SWTX stock currently worth $1,987,930.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
SpringWorks Therapeutics executives and other stock owners filed with the SEC include: